AU · rank #16 · 2026-10-20
IMCD
AMSTERDAM · EUR · $6.88B (USD)
The exact numbers the algorithm saw.
| Composite score Z-score blend of all factors below. | 0.179 |
|---|---|
| EPS revisions (30d) Change in consensus EPS estimate over the past 30 days ($/share). | +$0.06 |
| Net revisions (30d) Number of analysts revising upward minus downward. | 2 |
| Insider signal (90d) | — |
| Analyst upside Consensus target $117.36 | +13.9% |
| Momentum acceleration 3-month minus 12-month momentum. | +12.15% |
| Analyst rating 5 = Strong Buy, 1 = Strong Sell. | 4.29 |
| Gross margin TTM | +25.0% |
| 52w high | $105.55 |
| Market cap (USD) | $6.88B |
The AI research card
Independent qualitative review of each pick before the order is placed. On the rare day the research service is unavailable, the paper book trades on the quant ranking alone and no card appears here.
Summary
IMCD NV is a global distributor and formulator of specialty chemicals and ingredients, providing technical formulation, regulatory support, and supply-chain services.
Rationale
The analyst upside signal is backed by 100% positive EPS revision agreement and 13.9% analyst upside, underpinned by Q2 organic gross profit recovering to 7% growth and H1 constant-currency EBITA expanding 8%.
Material risks
- 1Disintermediation if primary specialty chemical suppliers or key downstream customers internalize technical sales, formulation, and distribution capabilities.
- 2Margin compression from softening specialty chemical pricing, compounded by financial leverage at 2.8x net debt to operating EBITDA.
AI verdict council
Each pick is reviewed independently by 3 models before any order. 2 of 3 voted to proceed.